Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
622 DKK | +3.84% | +6.60% | +66.67% |
04-04 | U.S. Futures Up, European Stocks Flat as Powell Reiterates Room for Rate Cuts This Year | DJ |
03-20 | Zealand Pharma A/S Approves Appointments to the Board | CI |
Business Summary
At the end of 2022, the Group had a portfolio of 7 products in clinical development (including 2 in phase III, 3 in phase II and 2 in phase I), and 4 products in preclinical development.
Number of employees: 253
Sales per Business
DKK in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Peptide-based Medicines
100.0
%
| 104 | 100.0 % | 343 | 100.0 % | +229.65% |
Sales per region
DKK in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Germany
85.9
%
| - | - | 294,509 | 85.9 % | - |
Denmark
12.9
%
| 35 | 33.7 % | 44,185 | 12.9 % | +126,142.86% |
United States
1.2
%
| 69 | 66.3 % | 4,094 | 1.2 % | +5,833.33% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 50 | 31/12/09 | |
Director of Finance/CFO | - | 31/10/22 | |
Ivan M. Møller
COO | Chief Operating Officer | 52 | 28/02/18 |
David M. Kendall
CTO | Chief Tech/Sci/R&D Officer | 62 | 01/06/22 |
Director/Board Member | 57 | - | |
Anna Krassowska
IRC | Investor Relations Contact | - | - |
Ravinder Chahil
LAW | General Counsel | 56 | - |
Human Resources Officer | 39 | 31/12/19 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Leonard Kruimer
BRD | Director/Board Member | 66 | 03/04/19 |
Chairman | 69 | 31/12/14 | |
Kirsten Drejer
BRD | Director/Board Member | 68 | 18/04/18 |
Director/Board Member | 58 | 03/04/19 | |
Director/Board Member | 65 | 03/04/19 | |
Director/Board Member | 57 | - | |
Anneline Nansen
BRD | Director/Board Member | 55 | 31/08/21 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 62,648,011 | 62,176,860 ( 99.25 %) | 373,134 ( 0.5956 %) | 99.25 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
ZEALAND PHARMA A/S 0.60% | 373,134 | 0.60% | 36,890,098 $ |
Company contact information
Sector
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+66.67% | 5.55B | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- ZEAL Stock
- Company Zealand Pharma A/S